Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
25
PYXS Quote, Financials, Valuation and Earnings
Last price:
$4.33
Seasonality move
:
63.88%
Day range:
$4.25 - $4.59
52-week range:
$0.83 - $5.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
93.87x
P/B ratio:
3.91x
Volume:
850.5K
Avg. volume:
770.4K
1-year change:
140%
Market cap:
$269M
Revenue:
$16.1M
EPS (TTM):
-$1.59
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PYXS
Pyxis Oncology, Inc.
|
-- | -$0.34 | -100% | -45.56% | $7.68 |
|
AKBA
Akebia Therapeutics, Inc.
|
$56.4M | -$0.01 | 20.82% | -95.21% | $5.40 |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$75.7M | $0.12 | -35.47% | 151.26% | $2.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
PTCT
PTC Therapeutics, Inc.
|
$175.5M | -$1.11 | 14.46% | -47.27% | $81.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PYXS
Pyxis Oncology, Inc.
|
$4.32 | $7.68 | $269M | -- | $0.00 | 0% | 93.87x |
|
AKBA
Akebia Therapeutics, Inc.
|
$1.59 | $5.40 | $421.9M | -- | $0.00 | 0% | 1.78x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$3.73 | $2.50 | $606.8M | 24.14x | $0.00 | 0% | 1.86x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
PFE
Pfizer Inc.
|
$25.70 | $29.04 | $146.1B | 14.98x | $0.43 | 6.69% | 2.34x |
|
PTCT
PTC Therapeutics, Inc.
|
$77.85 | $81.86 | $6.3B | 9.10x | $0.00 | 0% | 3.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PYXS
Pyxis Oncology, Inc.
|
21.71% | 3.830 | 13.82% | 4.01x |
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.611 | 29.46% | 1.76x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
179.07% | -0.236 | 280.72% | 1.08x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PTCT
PTC Therapeutics, Inc.
|
161.23% | 0.296 | 8.36% | 2.20x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PYXS
Pyxis Oncology, Inc.
|
-$527K | -$23.5M | -76.68% | -90.91% | -700.36% | -$13.3M |
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$121.6M | $77.7M | 9.89% | -- | 63.64% | $47.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PTCT
PTC Therapeutics, Inc.
|
$187.7M | $3.5M | -382.54% | -- | 1.65% | -$322.5M |
Pyxis Oncology, Inc. vs. Competitors
-
Which has Higher Returns PYXS or AKBA?
Akebia Therapeutics, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 0.92%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Akebia Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M -
What do Analysts Say About PYXS or AKBA?
Pyxis Oncology, Inc. has a consensus price target of $7.68, signalling upside risk potential of 77.66%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 239.62%. Given that Akebia Therapeutics, Inc. has higher upside potential than Pyxis Oncology, Inc., analysts believe Akebia Therapeutics, Inc. is more attractive than Pyxis Oncology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PYXSPyxis Oncology, Inc.7 1 0 AKBAAkebia Therapeutics, Inc.4 0 0 -
Is PYXS or AKBA More Risky?
Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.934%.
-
Which is a Better Dividend Stock PYXS or AKBA?
Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYXS or AKBA?
Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 93.87x versus 1.78x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYXSPyxis Oncology, Inc.93.87x -- -- -$22M AKBAAkebia Therapeutics, Inc.1.78x -- $58.8M $540K
-
Which has Higher Returns PYXS or IRWD?
Ironwood Pharmaceuticals, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 32.84%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M IRWDIronwood Pharmaceuticals, Inc.99.61% $0.23 $334.1M -
What do Analysts Say About PYXS or IRWD?
Pyxis Oncology, Inc. has a consensus price target of $7.68, signalling upside risk potential of 77.66%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $2.50 which suggests that it could fall by -32.98%. Given that Pyxis Oncology, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PYXSPyxis Oncology, Inc.7 1 0 IRWDIronwood Pharmaceuticals, Inc.0 4 0 -
Is PYXS or IRWD More Risky?
Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.177, suggesting its less volatile than the S&P 500 by 82.259%.
-
Which is a Better Dividend Stock PYXS or IRWD?
Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYXS or IRWD?
Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Pyxis Oncology, Inc.'s net income of -$22M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 24.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 93.87x versus 1.86x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYXSPyxis Oncology, Inc.93.87x -- -- -$22M IRWDIronwood Pharmaceuticals, Inc.1.86x 24.14x $122.1M $40.1M
-
Which has Higher Returns PYXS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of -255.85%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PYXS or NBY?
Pyxis Oncology, Inc. has a consensus price target of $7.68, signalling upside risk potential of 77.66%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Pyxis Oncology, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PYXSPyxis Oncology, Inc.7 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PYXS or NBY More Risky?
Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PYXS or NBY?
Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYXS or NBY?
Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Pyxis Oncology, Inc.'s net income of -$22M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 93.87x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYXSPyxis Oncology, Inc.93.87x -- -- -$22M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns PYXS or PFE?
Pfizer Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 21.32%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About PYXS or PFE?
Pyxis Oncology, Inc. has a consensus price target of $7.68, signalling upside risk potential of 77.66%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pyxis Oncology, Inc. has higher upside potential than Pfizer Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings PYXSPyxis Oncology, Inc.7 1 0 PFEPfizer Inc.7 15 1 -
Is PYXS or PFE More Risky?
Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock PYXS or PFE?
Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios PYXS or PFE?
Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Pyxis Oncology, Inc.'s net income of -$22M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 93.87x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYXSPyxis Oncology, Inc.93.87x -- -- -$22M PFEPfizer Inc.2.34x 14.98x $16.7B $3.6B
-
Which has Higher Returns PYXS or PTCT?
PTC Therapeutics, Inc. has a net margin of -650.85% compared to Pyxis Oncology, Inc.'s net margin of 7.53%. Pyxis Oncology, Inc.'s return on equity of -90.91% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PYXSPyxis Oncology, Inc.81.03% -$0.35 $87.9M PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M -
What do Analysts Say About PYXS or PTCT?
Pyxis Oncology, Inc. has a consensus price target of $7.68, signalling upside risk potential of 77.66%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $81.86 which suggests that it could grow by 5.15%. Given that Pyxis Oncology, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PYXSPyxis Oncology, Inc.7 1 0 PTCTPTC Therapeutics, Inc.7 5 1 -
Is PYXS or PTCT More Risky?
Pyxis Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.999%.
-
Which is a Better Dividend Stock PYXS or PTCT?
Pyxis Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PYXS or PTCT?
Pyxis Oncology, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Pyxis Oncology, Inc.'s net income of -$22M is lower than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Pyxis Oncology, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 9.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology, Inc. is 93.87x versus 3.60x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PYXSPyxis Oncology, Inc.93.87x -- -- -$22M PTCTPTC Therapeutics, Inc.3.60x 9.10x $211M $15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
